Otlertuzumab  (Synonyms: TRU-016)

Otlertuzumab (TRU-016) is a humanized anti-CD37 monoclonal antibody that can be used for cancer research^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Humanized

CD37^[1]

Otlertuzumab (TRU-016) in combination with Rituximab.html" class="link-product" target="_blank">Rituximab (HY-P9913), Rapamycin.html" class="link-product" target="_blank">Rapamycin (HY-10219), or Bendamustine.html" class="link-product" target="_blank">Bendamustine (HY-13567) increases cell killing of NHL cells^[2].
Otlertuzumab has the ability to bind to and kill CD37⁺ cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Otlertuzumab (TRU-016) in combination with Bendamustine.html" class="link-product" target="_blank">Bendamustine (HY-13567) displays greater anti-tumor activity than either agent alone against a follicular lymphoma tumor model in SCID mice^[2].
Otlertuzumab shows significant antitumor activity in mice bearing Ramos or Daudi tumor xenografts^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

104809.30

1372645-37-8

Liquid

Colorless to light yellow

[Otlertuzumab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [(scFv-heavy-kappa)G1-h-CH2-CH3]2

• 
  Immobilized CD37 Protein, Human can bind Otlertuzumab. The EC₅₀ for this effect is 37.2 ng/mL.

• [1]. Byrd JC, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood. 2014 Feb 27;123(9):1302-8.  [Content Brief]

  [2]. Baum P R, et al. Evaluation of the effect of TRU-016, an anti-CD37 directed SMIP in combination with other therapeutic drugs in models of non-Hodgkin's lymphoma. Journal of Clinical Oncology, 2009, 27(15_suppl): 8571-8571.

  [3]. Cerveny C G, et al. In vitro and in vivo anti-B cell lymphoma activities of TRU-016. Journal of Clinical Oncology, 2008, 26(15_suppl): 3074-3074.